Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

Transplantation

Volumn 66, Issue 1, 1998, Pages 29-37

  Gaber, Osama ^a   First, M Roy ^b   Tesi, Raymond J ^b   Gaston, Robert S ^b   Mendez, Robert ^b   Mulloy, Laura L ^b   Light, Jimmy A ^b   Gaber, Lillian W ^b   Squiers, Elizabeth ^b   Taylor, Rodney J ^b   Neylan, John F ^b   Steiner, Robert W ^b   Knechtle, Stuart ^b   Norman, Douglas J ^b   Shihab, Fuad ^b   Basadonna, Giacomo ^b   Brennan, Daniel C ^b   Hodge, Ernest E ^b   Kahan, Barry D ^b   Kahana, Lawrence ^b   Steinberg, Steven ^b   Woodle, E Steve ^b   Chan, Laurence ^b   Ham, John M ^b   Stratta, Robert J ^b   Wahlstrom, Erik ^b   Lamborn, Kathleen R ^b   Horn, H Rossiter ^b   Moran, Hana Berger ^b   Pouletty, Philippe ^b   Schroeder, Timothy J ^b   more..

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RABBITS;

EID: 0345676502     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199807150-00005     Document Type: Article

References (39)

1. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years: early events affecting transplant success. Transplantation 1992; 53: 59.
2. Fisher RA, Tchervankov JI, Schroeder TJ, et al. Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin. Transplant Proc 1991; 23: 1253.
3. Terasaki PI. Overview. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1991. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1992: 409.
4. Schweitzer EJ, Matas AS, Gillingham KJ, et al. Causes of renal allograft loss: progress in the 1980s, challenges for the 90s. Ann Surg 1991; 214: 679.
5. First MR, Schroeder TJ, Melvin DB, et al. OKT3 therapy in kidney, liver, heart, and pancreas transplantation. Clin Transplant 1988; 2: 185.
6. Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 1967; 124: 301.
7. Light JA, Alijani MR, Biggers JA, et al. Antilymphocyte globulin reverses irreversible allograft rejection. Transplant Proc 1981; 13: 475.
8. Howard RJ, Condie CM, Sutherland DER, Simmons RL, Najarian JS. The use of antilymphoblast globulin in treatment of renal allograft rejection. Transplantation 1977; 24: 410.
9. Mannick JA, Davis RC, Cooperband SR, et al. Clinical use of rabbit antihuman lymphocyte globulin in cadaver-kidney transplantation. N Engl J Med 1971; 284: 1109.
10. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
11. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697.
12. Hanto DW, Jendrisak MD, So SKS, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Transplantation 1994; 57: 377.
13. Ippoliti G, Negri M, Abelli P, et al. Preoperative prophylactic OKT3 vs. RATG, a randomized clinical study in heart transplant patients. Transplant Proc 1991; 23: 2272.
14. Grino JM, Castelao AM, Seron D, et al. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Am J Kidney Dis 1992; 20: 603.
15. Cole EH, Cattran DC, Farewell VT, et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994; 57: 60.
16. Alamartine E, Bellakoul R, Berthoux F. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Transplant Proc 1994; 26: 273.
17. Filo RS, Book V, Pescovitz MD, et al. Association of sensitization to horse antilymphocyte/thymocyte globulin with recipient age and decreased renal allograft survival rates. Transplant Proc 1993; 25: 577.
18. Bonnefoy-Bernard N, Flacher M, Revillard JP. Anti-proliferative effect of antilymphocyte globulins on B-cells and B-cell lines. Blood 1992; 79: 2164.
19. Soulillou JP, Cantarovich D, Le Manff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin 2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for the prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
20. Steininger R, Muhlbacher F, Hamilton G, et al. Comparison of CYA, OKT3, and ATG immunoprophylaxis in human liver transplantation. Transplant Proc 1991; 23: 2269.
21. Ippoliti G, Rovati B, Graffigna A, et al. Prophylactic use of rabbit ATG versus horse ALG in heart transplanted patients under Sandimmune therapy: clinical and immunological effects. Clin Transplant 1989; 3: 1.
22. Clark KR, Forsythe JLR, Shenton BK, et al. Flow-cytometric monitoring of ATG therapy for steroid-resistant rejection. Transplant Proc 1992; 24: 315.
23. LeFrançois N, Raffaele P, Martinenghi S, et al. Prophylactic polyclonal versus monoclonal antibodies in kidney and pancreas transplantation. Transplant Proc 1990; 22: 632.
24. O'Donaghue DJ, Johnson RW, Mallick NP, et al. Rabbit antithymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. Transplant Proc 1989; 21: 1736.
25. Filo RS, Smith EJ, Leapman SB. Reversal of acute cadaveric renal allograft rejection with adjunctive ATG therapy. Transplant Proc 1981; 13: 482.
26. Nowygard R, Appel G, Hardy MA. Use of ATG for reversal of acute allograft rejection. Transplant Proc 1981; 13: 409.
27. Shield CF III, Cosimi AB, Tolkoff-Rubin N, et al. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979; 28: 461.
28. Hardy M, Nowygard R, Ellberg A, et al. Use of ATG in the treatment of steroid-resistant rejection. Transplantation 1980; 29: 162.
29. Benvenisty AI, Tannenbaum GA, Cohen DJ, et al. Use of antithymocyte globulin and cyclosporine to treat steroid-resistant rejection episodes in renal transplant recipients. Transplant Proc 1987; 19: 1889.
30. Bourdage JS, Hamlin DM. Comparative polyclonal anti-thymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194.
31. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
32. COSTART, Fourth Edition. Rockville, MD: FDA Department of Health and Human Services, Center for Drug Evaluation and Research, 1994.
33. Kountz SL, Butt KHM, Rao TKS, et al. Antithymocyte globulin dosage and graft survival in renal transplantation. Transplant Proc 1977; 9: 1023.
34. Johnson K, Niblack G, Richie R, et al. Multicenter comparison of rejection reversal: rabbit antihuman lymphocyte serum (ATS) versus horse anti-human lymphocyte globulin (ATGAM). Transplant Proc 1989; 21: 1734.
35. Lum CT, Umen AJ, Kasiske B, et al. Clinical impact of replacing Minnesota anti-lymphocyte globulin with ATGAM. Transplantation 1995; 59: 371.
36. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
37. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy: a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992; 54: 50.
38. Guttmann RD, Fleming C. Sequential biologic immunosuppression: induction therapy with rabbit antithymocyte globulin. Clin Transplant 1997; 11: 185.
39. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435.